Literature DB >> 30312517

Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis.

O Musumeci1, S Marino2,3, F Granata2, R Morabito3, L Bonanno3, T Brizzi1,4, V Lo Buono3, F Corallo3, M Longo2, A Toscano1.   

Abstract

BACKGROUND AND
PURPOSE: Late-onset Pompe disease (LOPD) is a rare, multisystem disorder that is well established to mainly impair skeletal muscle function. Systematic studies exploring brain functions in LOPD are lacking. The aim of this study was to detect morphological and functional brain alterations as well as neuropsychological impairment in LOPD.
METHODS: We studied 21 patients (10 male, mean age 49 ± 18.4 years) with defined diagnosis of LOPD, divided into two groups: one with pre-symptomatic hyperCKemia with no muscle weakness and the second with limb-girdle muscle weakness. All patients underwent 3T magnetic resonance imaging (MRI) to obtain morphological/angiographic evaluation as well as normalized cortical brain volume and resting-state functional MRI. Fazekas score was applied to quantify white matter lesions, whereas Smoker's criteria were used to examine dolichoectasia. A complete neuropsychological assessment was performed.
RESULTS: The MRI data showed that 12/21 patients (57%) demonstrated signs of cerebral vasculopathy, with a Fazekas score >2 in 67%. According to Smoker's criteria, 11/21 patients (52%) had a dolichoectasia of the vertebrobasilar system; an intracranial aneurysm was detected in 3/21 patients (14%). Resting-state functional MRI demonstrated significantly decreased brain connectivity in the salience network with a more relevant reduction in the bilateral middle and superior frontal gyrus. Gray matter atrophy correlated with age and disease duration. A mild impairment in executive functions was also identified.
CONCLUSIONS: In this LOPD cohort the results showed morphological and functional brain alterations with mild neuropsychological dysfunction, mainly in the limb-girdle muscle weakness group. Cerebrovascular alterations seemed to be not related to common risk factors, suggesting a major role of enzymatic deficiency in the pathogenesis of brain abnormalities.
© 2018 EAN.

Entities:  

Keywords:  Fazekas score; Pompe disease; Smoker score; cerebrovascular abnormalities; functional magnetic resonance imaging; late-onset Pompe disease

Mesh:

Year:  2018        PMID: 30312517     DOI: 10.1111/ene.13835

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  17 in total

Review 1.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.

Authors:  Antonio Toscano; Carmelo Rodolico; Olimpia Musumeci
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

4.  Intracranial aneurysm management in patients with late-onset Pompe disease (LOPD).

Authors:  Francesca Granata; Antonio Toscano; Enricomaria Mormina; Olimpia Musumeci; Agostino Tessitore; Anna Ciranni; Graziana Tavilla; Antonio Pitrone; Sergio Lucio Vinci; Antonio Armando Caragliano; Marcello Longo
Journal:  Neurol Sci       Date:  2020-10-17       Impact factor: 3.307

Review 5.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

Review 6.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

7.  Novel approaches to quantify CNS involvement in children with Pompe disease.

Authors:  Aditi Korlimarla; Gail A Spiridigliozzi; Kelly Crisp; Mrudu Herbert; Steven Chen; Michael Malinzak; Mihaela Stefanescu; Stephanie L Austin; Heidi Cope; Kanecia Zimmerman; Harrison Jones; James M Provenzale; Priya S Kishnani
Journal:  Neurology       Date:  2020-06-09       Impact factor: 9.910

8.  Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.

Authors:  P Vanherpe; S Fieuws; A D'Hondt; C Bleyenheuft; P Demaerel; J De Bleecker; P Van den Bergh; J Baets; G Remiche; K Verhoeven; S Delstanche; M Toussaint; B Buyse; P Van Damme; C E Depuydt; K G Claeys
Journal:  Orphanet J Rare Dis       Date:  2020-04-05       Impact factor: 4.123

9.  Advancements in AAV-mediated Gene Therapy for Pompe Disease.

Authors:  S M Salabarria; J Nair; N Clement; B K Smith; N Raben; D D Fuller; B J Byrne; M Corti
Journal:  J Neuromuscul Dis       Date:  2020

10.  AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice.

Authors:  Brendan M Doyle; Sara M F Turner; Michael D Sunshine; Phillip A Doerfler; Amy E Poirier; Lauren A Vaught; Marda L Jorgensen; Darin J Falk; Barry J Byrne; David D Fuller
Journal:  Mol Ther Methods Clin Dev       Date:  2019-08-31       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.